Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the provided transcript. The company states it is a zero-debt company, indicating no outstanding debt on the balance sheet. Management emphasizes a strong balance sheet and the ability to continue investing in R&D and sales and marketing without requiring external fund-raising. No guidance or indication of plans to raise capital via equity issuance is provided in the earnings call.

Any current/future capex/capital investment/strategic investment?

Quick Heal continues to invest heavily in research and development (R&D) as a form of capital investment, especially in new product development for enterprise and consumer segments. FY '23 R&D expenses were ₹121 crore, with main components being manpower cost, technical collaboration charges, and cloud costs. Future R&D expense is expected to be maintained at 25% to 30% of revenue, reflecting ongoing investment in product features and capabilities. New products are planned for launch in H1 and H2 FY '24, with continuous feature additions to compete internationally. Sales and marketing expenses

Future growth expectations in sales/revenue/volumes?

Enterprise segment has shown consistent growth with over 11 straight quarters of year-on-year increase. Enterprise revenue surpassed 100 crore in FY '23, growing at over 20% CAGR in the last three years. Expectation to cross 300 crore consolidated revenue mark in FY '24 with H2 marking revival after earlier slowdown. Enterprise business projected to contribute at least 50% or more to total revenue in the next 4 to 6 quarters. Continued investments planned in R&D and sales & marketing to support long-term growth. New product launches in enterprise including endpoint protection, zero trust, and

Future growth expectations in earnings/operating earnings/profits/EPS?

The company does not provide specific guidance on revenue, costs, or earnings figures. (Navin Sharma, Page 7) H2 FY '23 faced an unexpected slowdown, but FY '24 is expected to be a year of revival with revenues crossing Rs. 300 crore. (Navin Sharma, Page 7) Enterprise segment has shown consistent growth with a 20% CAGR over the last three years and is expected to contribute at least 50% or more of total revenue in the next 4-6 quarters. (Sanjay Katkar, Page 7) R&D expenses will remain significant, targeting 25-30% of revenue to sustain product innovation and expansion. (Kailash Katkar, P

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Quick Heal Technologies. However, it notes that the Enterprise segment has been growing steadily with sustained quarter-on-quarter growth for nearly three years. The company sees significant growth potential in the Enterprise business, especially in the SMB and mid-size corporate segments. New product launches in Enterprise security (EDR, XDR, zero trust, data privacy) are expected to gain traction, with revenues anticipated from Q2 FY '24 onwards. Management indicates ongoing efforts to onboard

IN US

Sale is live|00:00:00left today

Quick Heal Technologies LtdQ1 FY23IT - Software

Quick Heal Technologies Ltd Q1 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹177P/E: 196.4Market Cap: ₹1.1K CrSector: IT - Software

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Enterprise segment has shown consistent growth with over 11 straight quarters of year-on-year increase.
→Enterprise revenue surpassed 100 crore in FY '23, growing at over 20% CAGR in the last three years.
→Expectation to cross 300 crore consolidated revenue mark in FY '24 with H2 marking revival after earlier slowdown.
→Enterprise business projected to contribute at least 50% or more to total revenue in the next 4 to 6 quarters.
→Continued investments planned in R&D and sales & marketing to support long-term growth.
→New product launches in enterprise including endpoint protection, zero trust, and data privacy expected to deliver revenues from Q2 FY '24.
→Consumer segment currently experiencing temporary contraction with anticipated bounce back from Q2 FY '24.
→Market expansion planned into mid-sized enterprise and government segments with significant growth opportunities.
→The company sees big potential to grow the enterprise business by expanding customer base and product range.

Margin guidance

Category 3

→The company does not provide specific guidance on revenue, costs, or earnings figures. (Navin Sharma, Page 7)
→H2 FY '23 faced an unexpected slowdown, but FY '24 is expected to be a year of revival with revenues crossing Rs. 300 crore. (Navin Sharma, Page 7)
→Enterprise segment has shown consistent growth with a 20% CAGR over the last three years and is expected to contribute at least 50% or more of total revenue in the next 4-6 quarters. (Sanjay Katkar, Page 7)
→R&D expenses will remain significant, targeting 25-30% of revenue to sustain product innovation and expansion. (Kailash Katkar, Pages 8-9)
→Sales and marketing costs are expected to remain stable or increase moderately to support new product launches and growth, especially in enterprise sales. (Navin Sharma, Page 11)
→Cost optimization measures have been implemented, aiming to improve profitability gradually. (Navin Sharma, Page 4)

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company states it is a zero-debt company, indicating no outstanding debt on the balance sheet.
→Management emphasizes a strong balance sheet and the ability to continue investing in R&D and sales and marketing without requiring external fund-raising.
→No guidance or indication of plans to raise capital via equity issuance is provided in the earnings call.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders for Quick Heal Technologies.
→However, it notes that the Enterprise segment has been growing steadily with sustained quarter-on-quarter growth for nearly three years.
→The company sees significant growth potential in the Enterprise business, especially in the SMB and mid-size corporate segments.
→New product launches in Enterprise security (EDR, XDR, zero trust, data privacy) are expected to gain traction, with revenues anticipated from Q2 FY '24 onwards.
→Management indicates ongoing efforts to onboard more customers and expects the Enterprise segment to contribute at least 50% of revenue in the next 4-6 quarters.
→No concrete figures for order backlog or pending orders were disclosed during the call.

Capex plans

Yes

→Quick Heal continues to invest heavily in research and development (R&D) as a form of capital investment, especially in new product development for enterprise and consumer segments.
→FY '23 R&D expenses were ₹121 crore, with main components being manpower cost, technical collaboration charges, and cloud costs.
→Future R&D expense is expected to be maintained at 25% to 30% of revenue, reflecting ongoing investment in product features and capabilities.
→New products are planned for launch in H1 and H2 FY '24, with continuous feature additions to compete internationally.
→Sales and marketing expenses are expected to stay similar next year with goals of substantially higher sales numbers.
→No explicit mention of other capital expenditures besides R&D investments and sales/marketing costs.
→The company emphasizes long-term investments despite short-term market challenges, maintaining a strong balance sheet and zero debt position.

How does Quick Heal Technologies Ltd rank vs peers in IT - Software?

Pro feature

1Quick Heal Technologies Ltd

Rev 3Mar 3

See full IT - Software sector rankings

Want more stocks like Quick Heal Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio